Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of Nemolizumab in Systemic Sclerosis
jRCT2031210481Phase 2Completed
- Sponsor
- Maruho Co., Ltd.
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nemolizumab in systemic sclerosis (SSc), sponsored by Maruho Co., Ltd. Primary endpoint: Change from baseline in modified Rodnan Skin Score (mRSS) at Week 24. Started Apr 2022; status: completed.
02
Drugs
nemolizumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2031210481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210481.